Skip to main content

Advertisement

Figure 3 | Diabetology & Metabolic Syndrome

Figure 3

From: Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Figure 3

Once daily injections of liraglutide do not affect insulin sensitivity but improve glucose tolerance in corticosterone-exposed mice. Male C57Bl/6J mice were treated with 1% ethanol (white squares and circles or white bars) or 100 μg/ml corticosterone (black squares and circles or black bars) via the drinking water together with once-daily injections of either PBS (squares or unstriped bars) or liraglutide at a final dose of 0.3 mg per kg body weight (circles or striped bars) for five consecutive weeks (n = 6). After four weeks of treatment insulin sensitivity was determined via an IPinsTT (A and B) and after five weeks of treatment glucose tolerance was determined via an IPGTT (C and D). During the IPGTT serum samples were collected and C-peptide levels were measured (E). Data is shown as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of corticosterone treatment and a # denotes a significant effect of liraglutide.

Back to article page